X4 Pharmaceuticals, Inc (XFOR) Nonoperating Income (Expense) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
X4 Pharmaceuticals, Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from 2017 to 2024.
  • X4 Pharmaceuticals, Inc Nonoperating Income (Expense) for the quarter ending March 31, 2024 was -$14.5 M, a 373% decline year-over-year.
  • X4 Pharmaceuticals, Inc Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was -$13.3 M, a 4222% decline year-over-year.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2023 was $6.43 M.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2022 was -$6.27 M, a 75.5% decline from 2021.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2021 was -$3.57 M, a 69.4% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$13.3 M -$14.5 M -$19.7 M -373% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $6.43 M $6.1 M +$9.62 M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$3.18 M $24.9 M +$26.4 M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$29.6 M -$29.9 M -$29.3 M -4585% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$308 K $5.29 M +$5.96 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$6.27 M -$3.51 M -$2.36 M -206% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$3.91 M -$1.45 M -$391 K -37.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$3.52 M -$638 K -$3 K -0.47% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$3.51 M -$674 K +$60 K +8.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$3.57 M -$1.15 M -$404 K -54.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 -$3.17 M -$1.05 M -$585 K -125% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$2.58 M -$635 K -$149 K -30.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$2.43 M -$734 K -$325 K -79.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$2.11 M -$745 K -$783 K -2061% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 -$1.33 M -$469 K +$269 K +36.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$1.6 M -$486 K -$517 K -1668% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$1.08 M -$409 K +$26 K +5.98% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$1.1 M $38 K +$3.27 M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 -$4.37 M -$738 K -$681 K -1195% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$3.69 M $31 K -$311 K -90.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$3.38 M -$435 K +$822 K +65.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$4.2 M -$3.23 M -$1.64 M -104% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-19
Q3 2018 -$2.56 M -$57 K -$1.51 M -104% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$1.04 M $342 K +$403 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$1.45 M -$1.26 M -$1.7 M -384% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $253 K -$1.58 M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $1.46 M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$61 K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $442 K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.